Jefferies Downgrades Spark Therapeutics (ONCE) to Hold Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts ONCE Hot Sheet
Price: $110.05 --0%
Rating Summary:
5 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 33
Rating Summary:
5 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 33
Join SI Premium – FREE
Jefferies analyst Michael Yee downgraded Spark Therapeutics (NASDAQ: ONCE) from Buy to Hold with a price target of $114.50 (from $85.00).
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $51.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Huber Research double downgrades Netflix to underweight, sets $70 price target
- JPMorgan Downgrades Localiza Rent a Car S.A. (RENT3:BZ) (LZRFY) to Neutral
- Evercore ISI Downgrades Foghorn Therapeutics (FHTX) to In Line
Create E-mail Alert Related Categories
DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
